Toxic shock syndrome secondary prevention

Secondary Prevention

Toxic shock syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Toxic Shock Syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Toxic shock syndrome secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Toxic shock syndrome secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Toxic shock syndrome secondary prevention
CDC on Toxic shock syndrome secondary prevention
Toxic shock syndrome secondary prevention in the news
Blogs on Toxic shock syndrome secondary prevention
Directions to Hospitals Treating Toxic shock syndrome
Risk calculators and risk factors for Toxic shock syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]

• First Sentences:

Secondary prevention strategies following [disease name] include [strategy 1], [strategy 2], and [strategy 3].

OR

The primary and secondary prevention strategies for [Disease Name] are the same.

Chemoprophylaxis of household contacts of STSS patients: Household contacts of people with STSS have a higher risk of invasive GAS infection compared to the general population. The Centers for Disease Control and Prevention have not made definite recommendations; some authors have recommended a 10-day course of cephalosporin

The risk of secondary cases of invasive disease is low at 2.9 per 1000. [null [82]] Several regimens have been successful in eradicating group A streptococcus from the pharynx of chronic carriers (i.e., rifampin plus intramuscular benzathine penicillin or a 10-day course of a second-generation cephalosporin or clindamycin). [null [107]] However, there are limited data concerning chemoprophylaxis for severe invasive group A streptococcal or staphylococcal infections.

American Academy of Pediatrics. Severe invasive group A streptococcal infection: a subject review. Pediatrics. 1998;101:136-140

Tanz RR, Poncher JR, Corydon KE, et al. Clindamycin treatment of chronic pharyngeal carriage of group a streptococci. J Pediatr. 1991;119:123-128